Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keppra in Early Psychosis
NCT03129360Phase 2Completed
- Sponsor
- NYU Langone Health
- Start
- Aug 2017
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of levetiracetam in psychosis, schizophrenia, schizoaffective disorder and 1 more, sponsored by NYU Langone Health. Primary endpoint: Cerebral Blood Flow at 2 hours. Started Aug 2017; status: completed.
02
Drugs
levetiracetam
03
Conditions
psychosisschizophreniaschizoaffective disorderschizophreniform disorder
Beyond the preview
Go deeper on NCT03129360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03129360.